Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$103.73 USD

103.73
9,295,764

-0.50 (-0.48%)

Updated Oct 29, 2024 04:00 PM ET

After-Market: $104.00 +0.27 (0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 16% (40 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer

by Zacks Equity Research

Merck (MRK) partners with Kelun-Biotech to develop seven antibody-drug conjugates targeting cancer indications. Merck will have an exclusive license to develop and commercialize these candidates.

Andrew Rocco headshot

Biotech is Set for a Blockbuster 2023: Here's Why

by Andrew Rocco

The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?

Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

Merck (MRK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $111.11 in the latest trading session, marking a +1.28% move from the prior day.

Merck (MRK), Seagen Keytruda-Padcev sBLAs Get FDA Priority Tag

by Zacks Equity Research

Merck (MRK) and Seagen's (SGEN) sBLAs seek approval of Padcev plus Keytruda for locally advanced or metastatic urothelial cancer in patients who are not eligible for cisplatin-containing chemotherapy.

AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.

Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DJD

The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant

by Zacks Equity Research

Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.

FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA

by Zacks Equity Research

The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More

by Kinjel Shah

Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.

Kinjel Shah headshot

4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023

by Kinjel Shah

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

Merck (MRK) Stock Moves -1.72%: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $109.63, marking a -1.72% move from the previous day.

Company News for Dec 15, 2022

by Zacks Equity Research

Companies in The News Are:BRZE,DAL,MRNA,MRK,SOFI

Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca

by Zacks Equity Research

Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.

Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study

by Zacks Equity Research

Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Kinjel Shah headshot

4 Large Drug Stocks to Watch in a Booming Industry

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

Andrew Rocco headshot

Trending Today: 5 Stocks in the News

by Andrew Rocco

So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.

Vaishali Doshi headshot

5 Dow Stocks That Helped the Index Minimize Loss in 2022

by Vaishali Doshi

Here we have shortlisted five stocks - CVX, MRK, AMGN, TRV and IBM- that have fared better than the Dow Jones Index this year and have more upside potential for investment consideration.

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

by Zacks Equity Research

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC

by Zacks Equity Research

The accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling cohort of the KRYSTAL-1 study.

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

by Zacks Equity Research

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Kinjel Shah headshot

3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns

by Kinjel Shah

Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.

The Zacks Analyst Blog Highlights Merck, Bristol-Myers Squibb and Deere

by Zacks Equity Research

Merck, Bristol-Myers Squibb and Deere are included in this Analyst Blog.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $108.78, moving -1.87% from the previous trading session.